CLL | Tumor

CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.

Better Data Needed to Approve Future PI3K Inhibitors for Blood Cancers, FDA Panel Recommends

April 25th 2022

A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.

Certain Blood Cancer Treatments Pulled from US Market After Treatment Results Fail to Show Improved Survival

April 21st 2022

The pharmaceutical company developing a combination regimen of ublituximab plus Ukoniq (known as U2) pulled the drug duo’s indications for the treatment of multiple types of blood cancer after clinical trial results fell short of improving overall survival.

FDA Places Partial Hold on Trial Investigating Novel Drug in Patients With Leukemia and Lymphoma

April 12th 2022

The FDA’s partial hold means that no new patients with either leukemia or lymphoma can be enrolled onto the trial.

Post-Treatment Venclexta Improves Outcomes and Is Well-Tolerated in CLL

April 12th 2022

Regardless of whether it was guided by minimal residual disease status or given at a fixed dosage, consolidation Venclexta proved to be beneficial in patients with chronic lymphocytic leukemia.

Immunocompromised: Navigating the COVID-19 Pandemic while Living with CLL

March 31st 2022

Learn about the disproportionate impact that the COVID-19 pandemic has on immunocompromised patients with chronic lymphocytic leukemia (CLL), and hear potential solutions from leading CLL experts.

Chronic Lymphocytic Leukemia: Cliff's Journey With CALQUENCE® (acalabrutinib)

March 25th 2022

This article was sponsored by AstraZeneca.

An ‘Equal Playing Field’ Makes up the Available Treatment Options for CLL

February 27th 2022

Regardless of a patient’s age, comorbidity status or disease risk, an expert from Memorial Sloan Kettering Cancer Center notes how targeted therapies have become the standard of care in treating chronic lymphocytic leukemia.

With No CAR-T Cell Therapies Approved for CLL, More Work is Needed to ‘Maximize’ These Treatments

February 14th 2022

More research is necessary, says an expert, to improve responses to CAR-T cell treatments in patients with chronic lymphocytic leukemia.

Calquence Linked to Fewer Heart-Related, Other Toxicities in Patients With CLL Than Imbruvica

January 7th 2022

Treatment with Calquence resulted in fewer toxicities, including atrial fibrillation, flutter and hypertension, in patients with previously treated chronic lymphocytic leukemia, compared with Imbruvica treatment, according to findings from the analysis of a phase 3 trial.

High-Frequency, Low-Dose Calquence-Rituxan Combo May Elicit Safe Responses in Previously Untreated CLL/SLL

December 20th 2021

The combination of Calquence and Rituxan may also be useful during the COVID-19 pandemic as it decreases infusion times and patient interactions, according to an expert.

5 Cancer Clinical Trials You May Have Missed

December 18th 2021

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

Calquence Remains Effective and Safe After 3 Years Compared With Standard of Care in Relapsed/Refractory Chronic Lymphocytic Leukemia

December 14th 2021

Calquence, a next-generation BTK inhibitor, significantly prolonged survival compared with standard of care, along with no new side effects at three years in chronic lymphocytic leukemia. These findings also pertained to some patients with high-risk genetic features.

Imbruvica And Rituxan Bests Standard-of-Care Regimen in Patients With Previously Untreated CLL

December 14th 2021

The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.

Patients With CLL Had Improved Quality of Life on Imbruvica Plus Rituxan

December 13th 2021

Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.

Cancer Clinical Trial Enrollment Is Low in the US, and Patient Depression and Anxiety May Play a Role

December 12th 2021

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

Adding Imbruvica to CAR-T Cell Therapy May Improve CLL Outcomes

November 17th 2021

Imbruvica plus Breyanzi, a CAR-T cell therapy, improved outcomes in patients with relapsed/refractory chronic lymphocytic leukemia, according to recent research.

CAR-T Cell Therapy Trial Currently Enrolling Patients With CLL and SLL

November 16th 2021

The TRANSCEND CLL 004 trial is currently enrolling patients to determine the efficacy of a CAR-T cell therapy.

‘Promising Times’ for Patients With CLL

October 16th 2021

A fixed-duration treatment regimen may result in better outcomes and less time in the hospital for patients with CLL.

Survival May Be Possible for Patients With CLL Even With Small Amounts of Disease After Treatment

October 14th 2021

Detectable amounts of minimal residual disease after treatment for CLL does not mean that all hope is lost for survival without disease progression.

WHO Adds Cancer and Smoking Cessation Medicines to Essential Drug List

October 6th 2021

The World Health Organization updated their Model Lists of Essential Medicines to include more cancer treatments, though some popular cancer drugs were excluded from the list.

3 Things Cancer Survivors Need to Remember: From Someone Who Has Been There

October 4th 2021

“Spending over a third of my life as a cancer survivor, I’ve learned a few lessons along the way,” said Lacey, who was diagnosed with chronic lymphocytic leukemia 13 years ago.

Which Mask Is Best for Protecting Patients With Cancer From a COVID-19 Variant?

September 27th 2021

An expert explains virus mutations, the Delta variant of COVID-19 and which masks offer the best protection for patients with cancer.

Blood Cancer Survivors Should Not Rely on COVID-19 Antibody Tests to Determine Immunity

August 24th 2021

Patients with blood cancers may be less likely to derive immunity from the COVID-19 vaccine, though antibody tests should not be the end-all-be-all in guiding their behavior.

BTK Inhibitors Are the Path Forward in Frontline CLL Treatment

August 19th 2021

Patients with chronic lymphocytic leukemia should talk to their doctors about the use of BTK inhibitors, as they produced promising outcomes in multiple trials.

CLL Treatment Represents ‘Very Optimistic Area’ in Research

August 9th 2021

Outcomes in patients with CLL continue to improve with the emergence of targeted drugs and immunotherapy.

Navigating Chronic Lymphocytic Leukemia Diagnosis and Staging

July 28th 2021

Although CLL follows a different staging format than other cancer types, diagnosing the disease properly can open the doors for more effective treatment and management strategies.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26th 2021

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Study Analyzes Quality of Life Research on Patients With CLL and Their Caregivers

July 22nd 2021

More research is needed on how a chronic lymphocytic leukemia diagnosis can affect patients and their caregivers.

Novel BTK Inhibitor Well Tolerated in Patients with CLL, Other B-Cell Malignancies

July 21st 2021

TG-1701 monotherapy or added to ublituximab and Ukoniq contributed to early complete responses in patients with B-cell malignancies.

Drug Duo Boosts Outcomes in Elderly Patients With CLL

July 18th 2021

Fixed-duration Venclexta plus Gazyva produced longer remissions than chemoimmunotherapy in elderly patients with chronic lymphocytic leukemia and other comorbidities.

NEXT PAGE
PREVIOUS PAGE